Rapid Micro Biosystems (RPID): Debts to Book Capitalization

High costs of reconfiguring IT validation and FDA approval create a robust moat for Rapid Micro Biosystems (RPID) purity control systems. Rapid Micro Biosystems (RPID) generates revenue by automating microbiological testing for pharmaceutical plants, leveraging strict regulatory standards and service revenue, which amounts to 1.40. This price chart reflects the trend and complements data on synergies with industry behemoths during the implementation of Growth Direct to accelerate the release of sterile drugs.

RPID Rapid Micro Biosystems Inc. Debt to Book Value Ratio (07/04/2022 - 10/27/2026)

Summary analytical data breakdowns for rapidmicrobio.com (RPID)

- price and consensus price forecast:

Stock Price Rapid Micro Biosystems, Inc.|RPID - Analyst Consensus Forecast

- market capitalization data:

Market Capitalization Rapid Micro Biosystems, Inc.|RPID - Full Takeover Company Value

- book capitalization data:

Net Assets per Single Share Rapid Micro Biosystems|RPID - Accounting Capitalization|Market Value to Book Value Ratio rapidmicrobio.com|RPID - Company Assets

- debt and liquidity data:

Debt to Equity Rapid Micro Biosystems|RPID - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio Rapid Micro Biosystems, Inc.|RPID - Company Cumulative Indebtedness|Debts to Book Capitalization Rapid Micro Biosystems, Inc.

Fundamental company analysis:Rapid Micro

To minimize financial risks, it is essential for an investor to assess the level of debt load relative to the issuer's equity. This indicator is calculated as the ratio of total liabilities to the book value of shareholder equity, whereby the ratio of total debt to book capital reveals how effectively Rapid Micro Biosystems (RPID) finances the automation of microbiological control for pharmaceutical partners while maintaining a balance between leverage and financial independence.

Competitors of Rapid Micro Biosystems